文献速递血栓与止血

血小板生成素受体激动剂联合免疫抑制药物治疗成人多重难治性免疫性血小板减少症:法国经验的更新

Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience.
PubMed 文献 · Br J Haematol · 2023-05-29

这项回顾性、多中心、观察性研究纳入39例对利妥昔单抗、血小板生成素受体激动剂(TPO-RA)及脾切除均无效的多重难治性ITP患者,给予TPO-RA联合免疫抑制药物治疗。77%的患者至少获得有效应答,中位起效时间30天,中位应答持续时间15个月;31%的患者出现与ITP治疗相关的严重不良事件。研究结论认为部分多重难治性ITP患者可通过该联合方案获得持久应答。

要点

  • 39例多重难治性ITP患者接受TPO-RA联合免疫抑制药物治疗,77%至少获得有效应答,其中24例完全应答。
  • 中位起效时间30天,中位应答持续时间15个月。
  • 31%的患者出现与ITP治疗相关的严重不良事件。

核心结论

  • 本研究证实部分多重难治性ITP患者通过TPO-RA联合免疫抑制药物治疗可获得持久应答。

研究设计与样本

  • 回顾性、多中心、观察性研究,纳入39例对利妥昔单抗、TPO-RA及脾切除均无效的多重难治性ITP患者,接受TPO-RA联合免疫抑制药物治疗。

主要发现

  • 39例患者中女性占67%,中位年龄59岁(范围21-96),中位ITP病程57个月(范围3-393),治疗启动时中位血小板计数10×10^9/L(范围1-35)。
  • 联合方案中位给药持续时间12个月(范围1-103),TPO-RA为艾曲泊帕(51%)或罗米司亭(49%),联合药物为吗替麦考酚酯(54%)、硫唑嘌呤(36%)、环磷酰胺(5%)、环孢素(3%)或依维莫司(3%)。
  • 30例患者(77%)至少获得有效应答(血小板计数≥30×10^9/L且较基线至少翻倍并持续至少3个月),其中24例完全应答(血小板计数>100×10^9/L持续至少3个月),中位起效时间30天(范围7-270),中位应答持续时间15个月(范围4-63)。
  • 31%的患者观察到与ITP治疗相关的严重不良事件。

关键数值与推荐

  • 有效应答定义为血小板计数≥30×10^9/L且较基线至少翻倍并持续至少3个月。
  • 完全应答定义为血小板计数>100×10^9/L持续至少3个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Combining drugs could be an effective option for treating multirefractory ITP, that is, patients not responding to rituximab, thrombopoietin receptor agonists (TPO-RA) and splenectomy. We conducted a retrospective, multicenter, observational study including multirefractory ITP patients who received a combination of a TPO-RA and an immunosuppressive drug. We included 39 patients (67% women, median age 59 years [range 21-96]), with a median ITP duration of 57 months [3-393] and a median platelet count at initiation of 10 × 109 /L [1-35]. The combination regimen was given for a median duration of 12 months [1-103] and included eltrombopag (51%) or romiplostim (49%), associated with mycophenolate mofetil (54%), azathioprine (36%), cyclophosphamide (5%), cyclosporin (3%) or everolimus (3%). Overall, 30 patients (77%) achieved at least a response (platelet count ≥30 × 109 /L and at least doubling baseline during at least 3 months), including 24 complete responses (platelet count >100 × 109 /L during at least 3 months) with a median time to response of 30 days [7-270] and a median duration of response of 15 months [4-63]. Severe adverse event related to ITP treatment was observed in 31%. In conclusion, this study confirms that some patients with multirefractory ITP can achieve long lasting response with this combination.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Crickx E, Ebbo M, Rivière E, et al. Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience. Br J Haematol. 2023. PMID: 37247631. doi:10.1111/bjh.18893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。